Gastrointestinal toxicities from cancer immunotherapy

Immunotherapy has transformed the treatment landscape for cancer, leading to durable remissions in patients with previously refractory disease. The promise of these treatments is limited by inflammatory toxicities that can target any system in the body. Gastrointestinal toxicities, in particular colitis and enterocolitis, are the most common severe toxicities induced by cancer immunotherapy and are a major reason for treatment discontinuation. Enjoy the discussion about the causes of these toxicities, the optimal workup and available treatment modalities. This knowledge is essential for enabling patients to derive the full benefit from cancer immunotherapy.